Logo

Amneal Reports the US FDA's Acceptance of BLA for Alymsys (biosimilar- bevacizumab)

Share this

Amneal Reports the US FDA's Acceptance of BLA for Alymsys (biosimilar- bevacizumab)

Shots:

  • The US FDA has accepted for review the BLA for bevacizumab- pursuant to section 351(k) pathway of the Public Health Service Act- and with anticipated BsUFA date in the Q2’22
  • Amneal and mAbxience reported that data supports the bio similarity of its Alymsys to the reference- Avastin. The company expects its initial biosimilar portfolio will include Filgrastim (biosimilar for Neupogen)- Pegfilgrastim (biosimilar for Neulasta) and Bevacizumab (biosimilar for Avastin)
  • Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA. The EMA has approved Alymsys in Feb’21

  | Ref: BUSINESS WIRE | Image: Amneal

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions